News
Rigel Publishes Data On REZLIDHIA In Post-Venetoclax Patients With Mutant IDH1 AML In Leukemia & Lymphoma
4 Apr 24
News, FDA
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $4
7 Mar 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $3
6 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
6 Mar 24
News, Price Target, Reiteration, Analyst Ratings
B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Maintains $1.25 Price Target
6 Mar 24
News, Price Target, Analyst Ratings
Earnings Scheduled For March 5, 2024
5 Mar 24
Earnings
Earnings Outlook For Rigel Pharmaceuticals
4 Mar 24
Earnings
12 Health Care Stocks Moving In Friday's Pre-Market Session
23 Feb 24
Movers
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
22 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Rigel Pharmaceuticals Acquires U.S. Rights To GAVRETO From Blueprint Medicines; Blueprint Receives $15M Purchase Price; Eligible For Up To $97.5M In Commercial Milestone Payments And $5M In Future Regulatory Milestone Payments
22 Feb 24
M&A, News
Press releases
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10 Apr 24
Press Releases
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
4 Apr 24
Press Releases
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
4 Apr 24
Press Releases
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
5 Mar 24
Earnings, Press Releases
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
28 Feb 24
News, Press Releases
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
22 Feb 24
Press Releases